Corcept Therapeutics (CORT) Change in Account Payables (2010 - 2026)

Corcept Therapeutics has reported Change in Account Payables for 17 years, with the latest figure at -$18.2 million in Q2 2026.

• Quarterly Change in Account Payables fell 312.51% year-over-year to -$18.2 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was -$9.0 million (down 304.05% YoY) and the FY2025 annual result came in at $25.1 million, up 1340.99% from the prior year.
• Change in Account Payables fell to -$18.2 million in Q2 2026 per CORT's latest filing, from -$7.6 million in the prior quarter.
• Over five years, Change in Account Payables peaked at $12.6 million in Q1 2025 and troughed at -$18.2 million in Q2 2026.
• A 5-year average of $407777.8 and a median of -$407000.0 in 2022 frame the typical range for Change in Account Payables.
• The sharpest annual moves came in 2023 and 2024: Change in Account Payables soared 5303.03% in 2023, then slumped 649.0% in 2024.
• Over 5 years, Change in Account Payables stood at $4.2 million in 2022, then tumbled by 84.98% to $637000.0 in 2023, then plunged by 587.6% to -$3.1 million in 2024, then jumped by 293.11% to $6.0 million in 2025, then plunged by 404.12% to -$18.2 million in 2026.
• According to Business Quant data, Change in Account Payables over the past three periods registered -$18.2 million, -$7.6 million, and $6.0 million for Q2 2026, Q1 2026, and Q4 2025 respectively.